AVECHO BIOTECHNOLOGY LIMITED - Announcements

0.00%

0.6¢

Market Cap $19.04M

Healthcare Biotechnology

Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company... Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The Company is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM. More

HELPING PATIENTS ON THEIR JOURNEY TO BETTER HEALTH

Little Green Pharma (ASX:LGP) to benefit as Denmark commits to cannabis pilot program.

Announcements

Filter Results

All Price Sensitive Only

AVE	Appendix 4D and Half-year Financial Report	PRICE SENSITIVE	28/08/25	728.75KB	Share
AVE	June 2025 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	30/07/25	243.18KB	Share
AVE	Phase III Insomnia Trial Recruitment Update	PRICE SENSITIVE	29/07/25	232.66KB	Share
AVE	Change in Substantial Holding		25/06/25	99.24KB	Share
AVE	Receipt of R&D Tax Incentive	PRICE SENSITIVE	28/05/25	131.11KB	Share
AVE	Change of Director's Interest Notice x4		27/05/25	1.25MB	Share
AVE	Notification regarding unquoted securities - AVE		27/05/25	17.98KB	Share
AVE	2025 Annual General Meeting Results		27/05/25	97.92KB	Share
AVE	Chair's Address and CEO Presentation		27/05/25	1.92MB	Share
AVE	Phase III Trial Update - New Sites Commence Recruitment	PRICE SENSITIVE	20/05/25	298.89KB	Share
AVE	March 2025 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	30/04/25	495.7KB	Share
AVE	Notice of Annual General Meeting/Proxy Form		24/04/25	1.02MB	Share
AVE	Application for quotation of securities - AVE		16/04/25	18.09KB	Share
AVE	Section 708A Cleansing Statement		16/04/25	93.07KB	Share
AVE	Avecho receives initial US$3M upfront payment from Sandoz	PRICE SENSITIVE	28/03/25	192.18KB	Share
AVE	Avecho to present at NWR Virtual Healthcare Conference		13/03/25	141.31KB	Share
AVE	Appendix 4G and Corporate Governance Statement		07/03/25	622.21KB	Share
AVE	Annual Report 31 December 2024		07/03/25	1.06MB	Share
AVE	Licensing Webinar and Presentation		04/03/25	1.52MB	Share
AVE	Avecho & Sandoz Sign Deal to Develop CBD for Insomnia in AUS	PRICE SENSITIVE	03/03/25	192.95KB	Share
AVE	Trading Halt	PRICE SENSITIVE	28/02/25	154.09KB	Share
AVE	Appendix 4E - Preliminary Final Report	PRICE SENSITIVE	28/02/25	362.32KB	Share
AVE	Response to ASX Price Query	PRICE SENSITIVE	14/02/25	208.56KB	Share
AVE	December 2024 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	30/01/25	292.65KB	Share
AVE	Change of Director's Interest Notice x3		02/12/24	705.87KB	Share
AVE	Notification of cessation of securities - AVE		02/12/24	12.83KB	Share
AVE	September 2024 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	29/10/24	171.32KB	Share
AVE	Appendix 4D and Half-year Financial Report	PRICE SENSITIVE	26/08/24	778.43KB	Share
AVE	June 2024 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	30/07/24	414.47KB	Share
AVE	Receipt of R&D Tax Incentive	PRICE SENSITIVE	13/06/24	98.44KB	Share
AVE	2024 Annual General Meeting Results		30/05/24	90.97KB	Share
AVE	Chair's Address and CEO Presentation	PRICE SENSITIVE	30/05/24	1.71MB	Share
AVE	Notification of cessation of securities - AVE		21/05/24	12.84KB	Share
AVE	First Patient dosed in Phase III insomnia trial	PRICE SENSITIVE	16/05/24	85.94KB	Share
AVE	March 2024 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	30/04/24	318.85KB	Share
AVE	Initial Director's Interest Notice		26/04/24	204.79KB	Share
AVE	Notice of Annual General Meeting/Proxy Form		26/04/24	414.48KB	Share
AVE	Notification regarding unquoted securities - AVE		26/04/24	15.95KB	Share
AVE	Appointment of New Director		26/04/24	73.35KB	Share
AVE	Monash Sleep Health Symposium		22/04/24	104.19KB	Share
AVE	Avecho commences Phase III insomnia trial	PRICE SENSITIVE	26/03/24	202.98KB	Share
AVE	Avecho to present at NWR Virtual Healthcare Conference		18/03/24	87.99KB	Share
AVE	Avecho meets TGA ahead of Phase III Clinical Trial	PRICE SENSITIVE	14/03/24	67.34KB	Share
AVE	AVE receives final ethics approval for Phase III CBD trial	PRICE SENSITIVE	07/03/24	74.51KB	Share
AVE	Appendix 4G and Corporate Governance Statement		29/02/24	574KB	Share
AVE	Appendix 4E and Annual Report 31 December 2023	PRICE SENSITIVE	29/02/24	1.4MB	Share
AVE	December 2023 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	31/01/24	299.59KB	Share
AVE	Expiry of Quoted Options		28/11/23	241.34KB	Share
AVE	Change of Director's Interest Notice x2		23/11/23	390.32KB	Share
AVE	Application for quotation of securities - AVE		22/11/23	30.11KB	Share
AVE	2023 General Meeting Results		09/11/23	473.79KB	Share
AVE	CEO Presentation		09/11/23	19.94MB	Share
AVE	September 2023 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	31/10/23	495.04KB	Share
AVE	Investor Presentation		13/10/23	1.2MB	Share
AVE	Phase III Clinical Trial Investor Webinar		11/10/23	57.35KB	Share
AVE	Notice of General Meeting/Proxy Form		09/10/23	856.3KB	Share
AVE	Application for quotation of securities - AVE		07/09/23	23.2KB	Share
AVE	Appendix 4D and Half-year Financial Report	PRICE SENSITIVE	31/08/23	1.37MB	Share
AVE	Reinstatement to Official Quotation	PRICE SENSITIVE	28/08/23	86.84KB	Share
AVE	Proposed issue of securities - AVE		28/08/23	29.46KB	Share
AVE	Proposed issue of securities - AVE		28/08/23	27.65KB	Share
AVE	Avecho raises further $6M for Phase III trial	PRICE SENSITIVE	28/08/23	91.03KB	Share
AVE	Voluntary Suspension	PRICE SENSITIVE	25/08/23	168.59KB	Share
AVE	Trading Halt	PRICE SENSITIVE	23/08/23	142.38KB	Share
AVE	June 2023 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	25/07/23	268.38KB	Share
AVE	Update - Application for quotation of securities - AVE		28/06/23	24.22KB	Share
AVE	Application for quotation of securities - AVE		28/06/23	24.72KB	Share
AVE	AVE CBD capsule passes two-year stability milestone	PRICE SENSITIVE	22/06/23	82.85KB	Share
AVE	AVE adds TPM cannabinoid gummies to portfolio	PRICE SENSITIVE	07/06/23	86.38KB	Share
AVE	USPTO allows new TPM manufacturing patent	PRICE SENSITIVE	29/05/23	79.48KB	Share
AVE	2023 Annual General Meeting Results		23/05/23	80.21KB	Share
AVE	Chair's Address and CEO Presentation		23/05/23	1.53MB	Share
AVE	Avecho licenses TPM for use in cancer drugs	PRICE SENSITIVE	22/05/23	116.81KB	Share
AVE	Withdrawal of AGM Resolutions 5(c) and 5(d)		18/05/23	202.07KB	Share
AVE	AVE commences manufacturing for Phase III trial	PRICE SENSITIVE	17/05/23	283.12KB	Share
AVE	Change in Substantial Holding		16/05/23	421.52KB	Share
AVE	Change of Director's Interest Notice x2		10/05/23	447.29KB	Share
AVE	Top 20 Option Holders		10/05/23	31.95KB	Share
AVE	Application for quotation of securities - AVE		10/05/23	27.01KB	Share
AVE	Results of Entitlement Offer	PRICE SENSITIVE	09/05/23	132.8KB	Share
AVE	Receipt of R&D Tax Incentive	PRICE SENSITIVE	02/05/23	201.89KB	Share
AVE	March 2023 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	28/04/23	363.87KB	Share
AVE	Notice of Annual General Meeting/Proxy Form		21/04/23	538.62KB	Share
AVE	Notice to Ineligible Foreign Shareholders		13/04/23	112.82KB	Share
AVE	Notice to Eligible Shareholders		13/04/23	133.79KB	Share
AVE	Letter to Optionholders		03/04/23	49.78KB	Share
AVE	Target Market Determination		03/04/23	145.57KB	Share
AVE	Proposed issue of securities - AVE		03/04/23	46.03KB	Share
AVE	Investor Presentation	PRICE SENSITIVE	03/04/23	1.68MB	Share
AVE	Prospectus	PRICE SENSITIVE	03/04/23	624.94KB	Share
AVE	Entitlement Offer to raise $11m for Phase 3 clinical trial	PRICE SENSITIVE	03/04/23	196.62KB	Share
AVE	Avecho to present at NWR Virtual Healthcare Conference		17/03/23	61.68KB	Share
AVE	Appendix 4G and Corporate Governance Statement		15/03/23	482.77KB	Share
AVE	Annual Report - 31 December 2022		15/03/23	1.3MB	Share
AVE	Appendix 4E - Preliminary Final Report	PRICE SENSITIVE	28/02/23	182.16KB	Share
AVE	Clinical CBD program expands with the Lambert Initiative	PRICE SENSITIVE	22/02/23	78.69KB	Share
AVE	December 2022 Quarterly Activities Report & Appendix 4C	PRICE SENSITIVE	31/01/23	273.71KB	Share
AVE	Athenex submits Avecho's phytonadione to FDA pre-IND	PRICE SENSITIVE	12/01/23	238.19KB	Share
AVE	Avecho receives ethics approval for Phase III CBD trial	PRICE SENSITIVE	22/12/22	131.46KB	Share
AVE	AVE signs development agreement with Perrigo	PRICE SENSITIVE	20/12/22	269.72KB	Share

AVE Appendix 4D and Half-year Financial Report
28/08/25	PRICE SENSITIVE	728.75KB	Share
AVE June 2025 Quarterly Activities Report & Appendix 4C
30/07/25	PRICE SENSITIVE	243.18KB	Share
AVE Phase III Insomnia Trial Recruitment Update
29/07/25	PRICE SENSITIVE	232.66KB	Share
AVE Change in Substantial Holding
25/06/25		99.24KB	Share
AVE Receipt of R&D Tax Incentive
28/05/25	PRICE SENSITIVE	131.11KB	Share
AVE Change of Director's Interest Notice x4
27/05/25		1.25MB	Share
AVE Notification regarding unquoted securities - AVE
27/05/25		17.98KB	Share
AVE 2025 Annual General Meeting Results
27/05/25		97.92KB	Share
AVE Chair's Address and CEO Presentation
27/05/25		1.92MB	Share
AVE Phase III Trial Update - New Sites Commence Recruitment
20/05/25	PRICE SENSITIVE	298.89KB	Share
AVE March 2025 Quarterly Activities Report & Appendix 4C
30/04/25	PRICE SENSITIVE	495.7KB	Share
AVE Notice of Annual General Meeting/Proxy Form
24/04/25		1.02MB	Share
AVE Application for quotation of securities - AVE
16/04/25		18.09KB	Share
AVE Section 708A Cleansing Statement
16/04/25		93.07KB	Share
AVE Avecho receives initial US$3M upfront payment from Sandoz
28/03/25	PRICE SENSITIVE	192.18KB	Share
AVE Avecho to present at NWR Virtual Healthcare Conference
13/03/25		141.31KB	Share
AVE Appendix 4G and Corporate Governance Statement
07/03/25		622.21KB	Share
AVE Annual Report 31 December 2024
07/03/25		1.06MB	Share
AVE Licensing Webinar and Presentation
04/03/25		1.52MB	Share
AVE Avecho & Sandoz Sign Deal to Develop CBD for Insomnia in AUS
03/03/25	PRICE SENSITIVE	192.95KB	Share
AVE Trading Halt
28/02/25	PRICE SENSITIVE	154.09KB	Share
AVE Appendix 4E - Preliminary Final Report
28/02/25	PRICE SENSITIVE	362.32KB	Share
AVE Response to ASX Price Query
14/02/25	PRICE SENSITIVE	208.56KB	Share
AVE December 2024 Quarterly Activities Report & Appendix 4C
30/01/25	PRICE SENSITIVE	292.65KB	Share
AVE Change of Director's Interest Notice x3
02/12/24		705.87KB	Share
AVE Notification of cessation of securities - AVE
02/12/24		12.83KB	Share
AVE September 2024 Quarterly Activities Report & Appendix 4C
29/10/24	PRICE SENSITIVE	171.32KB	Share
AVE Appendix 4D and Half-year Financial Report
26/08/24	PRICE SENSITIVE	778.43KB	Share
AVE June 2024 Quarterly Activities Report & Appendix 4C
30/07/24	PRICE SENSITIVE	414.47KB	Share
AVE Receipt of R&D Tax Incentive
13/06/24	PRICE SENSITIVE	98.44KB	Share
AVE 2024 Annual General Meeting Results
30/05/24		90.97KB	Share
AVE Chair's Address and CEO Presentation
30/05/24	PRICE SENSITIVE	1.71MB	Share
AVE Notification of cessation of securities - AVE
21/05/24		12.84KB	Share
AVE First Patient dosed in Phase III insomnia trial
16/05/24	PRICE SENSITIVE	85.94KB	Share
AVE March 2024 Quarterly Activities Report & Appendix 4C
30/04/24	PRICE SENSITIVE	318.85KB	Share
AVE Initial Director's Interest Notice
26/04/24		204.79KB	Share
AVE Notice of Annual General Meeting/Proxy Form
26/04/24		414.48KB	Share
AVE Notification regarding unquoted securities - AVE
26/04/24		15.95KB	Share
AVE Appointment of New Director
26/04/24		73.35KB	Share
AVE Monash Sleep Health Symposium
22/04/24		104.19KB	Share
AVE Avecho commences Phase III insomnia trial
26/03/24	PRICE SENSITIVE	202.98KB	Share
AVE Avecho to present at NWR Virtual Healthcare Conference
18/03/24		87.99KB	Share
AVE Avecho meets TGA ahead of Phase III Clinical Trial
14/03/24	PRICE SENSITIVE	67.34KB	Share
AVE AVE receives final ethics approval for Phase III CBD trial
07/03/24	PRICE SENSITIVE	74.51KB	Share
AVE Appendix 4G and Corporate Governance Statement
29/02/24		574KB	Share
AVE Appendix 4E and Annual Report 31 December 2023
29/02/24	PRICE SENSITIVE	1.4MB	Share
AVE December 2023 Quarterly Activities Report & Appendix 4C
31/01/24	PRICE SENSITIVE	299.59KB	Share
AVE Expiry of Quoted Options
28/11/23		241.34KB	Share
AVE Change of Director's Interest Notice x2
23/11/23		390.32KB	Share
AVE Application for quotation of securities - AVE
22/11/23		30.11KB	Share
AVE 2023 General Meeting Results
09/11/23		473.79KB	Share
AVE CEO Presentation
09/11/23		19.94MB	Share
AVE September 2023 Quarterly Activities Report & Appendix 4C
31/10/23	PRICE SENSITIVE	495.04KB	Share
AVE Investor Presentation
13/10/23		1.2MB	Share
AVE Phase III Clinical Trial Investor Webinar
11/10/23		57.35KB	Share
AVE Notice of General Meeting/Proxy Form
09/10/23		856.3KB	Share
AVE Application for quotation of securities - AVE
07/09/23		23.2KB	Share
AVE Appendix 4D and Half-year Financial Report
31/08/23	PRICE SENSITIVE	1.37MB	Share
AVE Reinstatement to Official Quotation
28/08/23	PRICE SENSITIVE	86.84KB	Share
AVE Proposed issue of securities - AVE
28/08/23		29.46KB	Share
AVE Proposed issue of securities - AVE
28/08/23		27.65KB	Share
AVE Avecho raises further $6M for Phase III trial
28/08/23	PRICE SENSITIVE	91.03KB	Share
AVE Voluntary Suspension
25/08/23	PRICE SENSITIVE	168.59KB	Share
AVE Trading Halt
23/08/23	PRICE SENSITIVE	142.38KB	Share
AVE June 2023 Quarterly Activities Report & Appendix 4C
25/07/23	PRICE SENSITIVE	268.38KB	Share
AVE Update - Application for quotation of securities - AVE
28/06/23		24.22KB	Share
AVE Application for quotation of securities - AVE
28/06/23		24.72KB	Share
AVE AVE CBD capsule passes two-year stability milestone
22/06/23	PRICE SENSITIVE	82.85KB	Share
AVE AVE adds TPM cannabinoid gummies to portfolio
07/06/23	PRICE SENSITIVE	86.38KB	Share
AVE USPTO allows new TPM manufacturing patent
29/05/23	PRICE SENSITIVE	79.48KB	Share
AVE 2023 Annual General Meeting Results
23/05/23		80.21KB	Share
AVE Chair's Address and CEO Presentation
23/05/23		1.53MB	Share
AVE Avecho licenses TPM for use in cancer drugs
22/05/23	PRICE SENSITIVE	116.81KB	Share
AVE Withdrawal of AGM Resolutions 5(c) and 5(d)
18/05/23		202.07KB	Share
AVE AVE commences manufacturing for Phase III trial
17/05/23	PRICE SENSITIVE	283.12KB	Share
AVE Change in Substantial Holding
16/05/23		421.52KB	Share
AVE Change of Director's Interest Notice x2
10/05/23		447.29KB	Share
AVE Top 20 Option Holders
10/05/23		31.95KB	Share
AVE Application for quotation of securities - AVE
10/05/23		27.01KB	Share
AVE Results of Entitlement Offer
09/05/23	PRICE SENSITIVE	132.8KB	Share
AVE Receipt of R&D Tax Incentive
02/05/23	PRICE SENSITIVE	201.89KB	Share
AVE March 2023 Quarterly Activities Report & Appendix 4C
28/04/23	PRICE SENSITIVE	363.87KB	Share
AVE Notice of Annual General Meeting/Proxy Form
21/04/23		538.62KB	Share
AVE Notice to Ineligible Foreign Shareholders
13/04/23		112.82KB	Share
AVE Notice to Eligible Shareholders
13/04/23		133.79KB	Share
AVE Letter to Optionholders
03/04/23		49.78KB	Share
AVE Target Market Determination
03/04/23		145.57KB	Share
AVE Proposed issue of securities - AVE
03/04/23		46.03KB	Share
AVE Investor Presentation
03/04/23	PRICE SENSITIVE	1.68MB	Share
AVE Prospectus
03/04/23	PRICE SENSITIVE	624.94KB	Share
AVE Entitlement Offer to raise $11m for Phase 3 clinical trial
03/04/23	PRICE SENSITIVE	196.62KB	Share
AVE Avecho to present at NWR Virtual Healthcare Conference
17/03/23		61.68KB	Share
AVE Appendix 4G and Corporate Governance Statement
15/03/23		482.77KB	Share
AVE Annual Report - 31 December 2022
15/03/23		1.3MB	Share
AVE Appendix 4E - Preliminary Final Report
28/02/23	PRICE SENSITIVE	182.16KB	Share
AVE Clinical CBD program expands with the Lambert Initiative
22/02/23	PRICE SENSITIVE	78.69KB	Share
AVE December 2022 Quarterly Activities Report & Appendix 4C
31/01/23	PRICE SENSITIVE	273.71KB	Share
AVE Athenex submits Avecho's phytonadione to FDA pre-IND
12/01/23	PRICE SENSITIVE	238.19KB	Share
AVE Avecho receives ethics approval for Phase III CBD trial
22/12/22	PRICE SENSITIVE	131.46KB	Share
AVE AVE signs development agreement with Perrigo
20/12/22	PRICE SENSITIVE	269.72KB	Share

REFRESH

1 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.6¢		Change 0.000(0.00%)		Mkt cap ! $19.04M

Open	High	Low	Value	Volume
0.7¢	0.7¢	0.6¢	$344	55.81K

Buyers (Bids)

No.	Vol.	Price($)
21	10913781	0.6¢

Sellers (Offers)

Price($)	Vol.	No.
0.7¢	516922	2

View Market Depth

No.	Vol.	Price($)
21	10913781	0.006
25	22285760	0.005
18	11801847	0.004
19	11655017	0.003
9	7655014	0.002

Price($)	Vol.	No.
0.007	516922	2
0.008	7751019	14
0.009	8841785	11
0.010	2198526	9
0.011	4535565	3

Last trade - 16.10pm 12/09/2025 (20 minute delay)

AVE (ASX) Chart

AVECHO BIOTECHNOLOGY LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories